Loss of anti-spike antibodies following mRNA vaccination for COVID-19 among patients with multiple myeloma
© 2023 The Authors. Cancer Reports published by Wiley Periodicals LLC..
BACKGROUND: Multiple myeloma (MM) patients have variable responses to mRNA vaccination to COVID-19. Little is known regarding their vaccine-induced antibody levels over time.
METHODS: We monitored spike IgG antibody levels over 24 weeks among a subset of 18 MM patients who showed a full response after two mRNA vaccinations.
RESULTS: MM patients had a more rapid decline in antibody levels as compared to eight healthy controls, with power law half-lives of 72 days (vs. 107 days) and exponential half-lives of 37 days (vs. 51 days). The patients with longer SARS-CoV-2 antibody half-lives were more likely to have undetectable monoclonal protein than those with shorter half-lives, suggesting better disease control may correlate with longer duration of vaccine-induced antibodies. Regardless, by 16 weeks post-second dose of mRNA vaccination, the majority of patients had antibody levels below 250 binding arbitrary units per milliliter, which would be unlikely to contribute to preventing COVID-19.
CONCLUSIONS: Thus, even MM patients who respond adequately to vaccination are likely to require more frequent booster doses than the general population.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:6 |
|---|---|
| Enthalten in: |
Cancer reports (Hoboken, N.J.) - 6(2023), 5 vom: 01. Mai, Seite e1803 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Stampfer, Samuel D [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies |
|---|
| Anmerkungen: |
Date Completed 12.05.2023 Date Revised 15.05.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/cnr2.1803 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM353974579 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM353974579 | ||
| 003 | DE-627 | ||
| 005 | 20231226061223.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/cnr2.1803 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1179.xml |
| 035 | |a (DE-627)NLM353974579 | ||
| 035 | |a (NLM)36891732 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Stampfer, Samuel D |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Loss of anti-spike antibodies following mRNA vaccination for COVID-19 among patients with multiple myeloma |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 12.05.2023 | ||
| 500 | |a Date Revised 15.05.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 The Authors. Cancer Reports published by Wiley Periodicals LLC. | ||
| 520 | |a BACKGROUND: Multiple myeloma (MM) patients have variable responses to mRNA vaccination to COVID-19. Little is known regarding their vaccine-induced antibody levels over time | ||
| 520 | |a METHODS: We monitored spike IgG antibody levels over 24 weeks among a subset of 18 MM patients who showed a full response after two mRNA vaccinations | ||
| 520 | |a RESULTS: MM patients had a more rapid decline in antibody levels as compared to eight healthy controls, with power law half-lives of 72 days (vs. 107 days) and exponential half-lives of 37 days (vs. 51 days). The patients with longer SARS-CoV-2 antibody half-lives were more likely to have undetectable monoclonal protein than those with shorter half-lives, suggesting better disease control may correlate with longer duration of vaccine-induced antibodies. Regardless, by 16 weeks post-second dose of mRNA vaccination, the majority of patients had antibody levels below 250 binding arbitrary units per milliliter, which would be unlikely to contribute to preventing COVID-19 | ||
| 520 | |a CONCLUSIONS: Thus, even MM patients who respond adequately to vaccination are likely to require more frequent booster doses than the general population | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a antibodies | |
| 650 | 4 | |a half-life | |
| 650 | 4 | |a multiple myeloma | |
| 650 | 4 | |a vaccination | |
| 650 | 7 | |a RNA, Messenger |2 NLM | |
| 700 | 1 | |a Bujarski, Sean |e verfasserin |4 aut | |
| 700 | 1 | |a Goldwater, Marissa-Skye |e verfasserin |4 aut | |
| 700 | 1 | |a Jew, Scott |e verfasserin |4 aut | |
| 700 | 1 | |a Regidor, Bernard |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Haiming |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Ning |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Mingjie |e verfasserin |4 aut | |
| 700 | 1 | |a Fung, Eddie |e verfasserin |4 aut | |
| 700 | 1 | |a Swift, Regina |e verfasserin |4 aut | |
| 700 | 1 | |a Beatty, Bethany |e verfasserin |4 aut | |
| 700 | 1 | |a Eshaghian, Shahrooz |e verfasserin |4 aut | |
| 700 | 1 | |a Berenson, James R |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancer reports (Hoboken, N.J.) |d 2018 |g 6(2023), 5 vom: 01. Mai, Seite e1803 |w (DE-627)NLM309522617 |x 2573-8348 |7 nnns |
| 773 | 1 | 8 | |g volume:6 |g year:2023 |g number:5 |g day:01 |g month:05 |g pages:e1803 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/cnr2.1803 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 6 |j 2023 |e 5 |b 01 |c 05 |h e1803 | ||